A lesson from vorinostat in pleural mesothelioma

The Lancet Oncology

Volumn 16, Issue 4, 2015, Pages 359-360

  Garassino, Marina Chiara ^a   Marsoni, Silvia ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b FPO IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROXAMIC ACID;

FEMALE; HUMAN; LUNG NEOPLASMS; MALE; MESOTHELIOMA; NEOPLASM RECURRENCE, LOCAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; NEOPLASM RECURRENCE, LOCAL;

EID: 84934280540     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70084-7     Document Type: Note

References (10)

1. Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005, 92:587-593.
2. Stahel RA, Weder W, Lievens Y, Felip E Malignant Pleural Mesothelioma: ESMO Clinical Practice Guidelines. Ann Oncol 2010, 21:vi126-vi128. on behalf of the ESMO working group.
3. Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 2015, published online March 20. http://dx.doi.org/10.1016/S1470-2045(15)70056-2.
4. Marsoni S, Damia G, Camboni G A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics 2008, 3:164-171.
5. Paik PK, Krug LM Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol 2010, 5:275-279.
6. Kilkenny C, Browne WJ, Cuthill IC, et al. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010, 8:e1000412.
7. Contopoulos-Ioannidis DG, Alexiou GA, Gouvias TC, et al. Life cycle of translational research for medical interventions. Science 2008, 321:1298-1299.
8. Arrowsmith J A decade of change. Nat Rev Drug Discov 2012, 11:17-18.
9. Zucali PA, Simonelli M, Michetti G Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012, 75:360-367.
10. Casali PG, Bruzzi P, Bogaerts J, et al. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. Ann Oncol 2015, 26:300-306. on behalf of the Rare Cancers Europe (RCE) Consensus Panel.